Clinical trials: Sadness
Generalized Anxiety Disorder (GAD), Anxiety, Separation
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
This study will evaluate the safety and tolerability of SPD503 in subjects aged 6-17 years with GAD, SAD, or SoP based on treatment emergent adverse events (TEAEs), vital signs and ECGs.
- Conditions
- Generalized Anxiety Disorder (GAD), Anxiety, Separation, Phobia, Social
- Trial name
- NCT01470469
- Testing
- SPD503 (extended-release Guanfacine hydrochloride)
- Where
- 33 sites in United States
- Volunteers
- 83 people
- Sponsor
- Shire
Healthy Volunteers
A Combined SAD and MAD Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of IFB-088
This is the first study of single and multiple doses of IFB-088 in human subjects. The current study is designed to assess in the first part, the safety, tolerability, plasma and urine pharmacokinetics (PK) of single oral doses…
- Trial name
- NCT03610334
- Testing
- IFB-088 (2.5-60.0mg) oral capsule, IFB-088 (15.0-50.0mg) oral capsule
- Where
- 2 sites in France
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- InFlectis BioScience
General Anxiety Disorder, Social Anxiety Disorder
A 10 Week Open-Label Pilot Study to Evaluate the Effectiveness and Safety of Memantine(Namenda) as Augmentation Therapy in Patients With Generalized Anxiety Disorder
This study is being conducted to evaluate the safety and effectiveness of memantine Add-On treatment of patients who are currently taking an SNRI or SSRI and who remain anxious and symptomatic despite treatment.
- Trial name
- NCT00411398
- Testing
- Namenda/Memantine
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- State University of New York - Upstate Medical University
Healthy Male Subjects, Cardiovascular Disease
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Male Subjects
This is a phase I, randomised, single-blind, placebo-controlled, first-in-human (FIH) single and multiple ascending dose study consisting of two parts (Part A [SAD] and Part B [MAD]) to assess the safety, tolerability…
- Trial name
- NCT02632526
- Testing
- AZD5718 oral suspension crystalline form (1 to 100 mg/mL) (Part A), AZD5718 oral suspension amorphous (1 to 100 mg/mL) (Part A), AZD5718 oral suspension amorphous (1 to 100 mg/mL) (Part B)
- Where
- United Kingdom
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Major Depressive Disorder, Insomnia
Time to Remission of Depressive Symptoms With Combined SSRI and Ramelteon
Hypothesis I: Patients in the SSRI + ramelteon treatment group will achieve remission (defined as an IDS-C30 score of 11 or less) more quickly than those in the SSRI + placebo group.
- Trial name
- TAKEDA (NCT00642694)
- Testing
- Escitalopram, Ramelteon
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Texas Southwestern Medical Center
Healthy Volunteers, Moderate to Severe Alzheimer Patients
A Randomized SAD and MAD Study Evaluating the Safety and Tolerability of RPh201 in Healthy Subjects and in Adults With Alzheimer's Disease
This is a dual-centre, Phase I/IIa study, in healthy subjects and subjects with AD to investigate the safety, tolerability, cognitive, and behavioural effects of RPh201.
- Trial name
- NCT01513967
- Testing
- RPh201, botanical drug product
- Where
- 2 sites in Canada
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Regenera Pharma Ltd
Social Anxiety Disorder
Open-label Safety Trial of PH94B in Social Anxiety Disorder (SAD)
This study evaluates the safety and tolerability of PH94B with repeated dosing over a period of up to 12 months. Participating subjects will use PH94B up to 4 times a day when they encounter anxiety-provoking situations in daily…
- Trial name
- NCT05030350
- Testing
- PH94B
- Where
- 3 sites in United States
- Volunteers
- 481 people
- Sponsor
- VistaGen Therapeutics, Inc.
Healthy Volunteers
AZD8108 SAD/MAD in Healthy Volunteers
This is a randomized, double-blind, placebo-controlled study of single and multiple ascending dosage levels of AZD8108 in healthy volunteers.
- Trial name
- AZD8108 (NCT02248818)
- Testing
- AZD8108
- Where
- United States
- Volunteers
- 258 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Chronic Hypoparathyroidism
AZP-3601 SAD and MAD Study in Healthy Subjects and Patients With Hypoparathyroidism
This study is investigating the safety, tolerability, pharmacodynamics and pharmacokinetics of AZP-3601 following single and repeated administration in both healthy volunteers and patients with chronic hypoparathyroidism (cHP)…
- Trial name
- NCT05239221
- Testing
- AZP-3601
- Where
- 2 sites in Hungary, Netherlands
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- Alexion Pharmaceuticals, Inc.
Mild-Moderate Alzheimer's Disease, Healthy Elderly
SAD/MAD Study to Assess Safety, Tolerability, PK & PD of MEDI1814 in Subjects With Mild-Moderate Alzheimer's Disease.
The purpose of this study is to assess the safety, drug levels and effects on the body of 1 or 3 injections of MEDI1814, in people with mild to moderate Alzhiemer's Disease or healthy elderly people.
- Trial name
- NCT02036645
- Testing
- MEDI1814 for IV injection, MEDI1814 for Subcutaneous Injection
- Where
- 10 sites in United States
- Volunteers
- 77 people
- Sponsor
- AstraZeneca
Alzheimer Disease
Study Evaluating Single Ascending Doses of AAB-001 Vaccine SAD Japanese Patients With Alzheimers Disease
Evaluate safety, tolerability, and pharmacokinetics of single doses of the investigational AAB-001 Vaccine in Japanese patients with Alzheimer's disease.
- Trial name
- NCT00397891
- Testing
- bapineuzumab
- Where
- 4 sites in Japan
- Volunteers
- 80 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Pregnancy Related, Postpartum Sadness
Fourth Trimester - A Web-based Tool for Postpartum Care to Address the Needs of Underserved Women
The postpartum period is a critical time for both maternal and child health, and more than half of all maternal deaths occur postpartum, from one day to one year after birth.
- Trial name
- NCT04475718
- Testing
- Fourth Trimester Mobile Tool
- Where
- 2 sites in United States
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Carelon Research
Major Depressive Disorder
Omega-3 Fatty Acids as Adjunct Treatment for Major Depressive Disorder
The primary objective of the study was to determine the effects of 10-week adjunctive supplementation with 2 doses of LCn-3 fatty acids (fish oil) on cortical functional activity and biochemistry in adolescents with MDD.
- Trial name
- NCT00511810
- Testing
- Low Dose Fish Oil, High Dose Fish Oil
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Cincinnati
Seasonal Affective Disorder
A Trial of Negative Ion Generation Versus Light-Emitting Diode Phototherapy for Seasonal Affective Disorder (SAD)
This is a randomized, controlled clinical trial of inactivated negative ion generation or light-emitting photodiode therapy for Seasonal Affective Disorder (SAD, winter depression), for subjects with a DSM IV diagnosis of Major…
- Trial name
- NCT00809523
- Testing
- Negative Ion Generator, Light-emitting Photodiode light treatment device
- Where
- 8 sites in United States, Canada and 1 more
- Volunteers
- 106 people
- Sponsor
- Yale University
Tuberculosis, Tuberculosis, Pulmonary
A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adults
Partially-Blinded, Placebo-Controlled, Randomized, Single Ascending Dose (SAD) with a Food Effect Cohort to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adults.
- Trial name
- NCT03758612
- Testing
- TBI-223 oral suspension, TBI-223 enteric capsule, TBI-223 SR Tablet Prototype 1
- Where
- United States
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Global Alliance for TB Drug Development
Urinary Tract Infections
Safety, Tolerability and Pharmacokinetic Investigation of GSK3882347 in Healthy Participants.
This is a phase 1, 2-part, double-blind (sponsor-unblinded), randomized, placebo-controlled, first time in human (FTIH) study, that includes both single-ascending and multiple-ascending dose phase to assess the safety…
- Trial name
- NCT04488770
- Testing
- GSK3882347
- Where
- United Kingdom
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Social Anxiety Disorder
Ketamine Infusion for Social Anxiety Disorder
Social Anxiety Disorder (SAD) is common and causes significant impairment. First-line treatments for Social Anxiety Disorder are only partially effective.
- Trial name
- NCT02083926
- Testing
- Ketamine, Saline
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Yale University
Hallux Valgus Deformity
A Phase 1 Study of Intraoperative Administration of CA-008 for the Correction of Hallux Valgus Deformity
This is a single-center, randomized, double-blind, placebo-controlled, single ascending dose, sequential-group Phase 1 study. The study will be conducted utilizing a cohort design, with sequential groups of 8 subjects.
- Trial name
- NCT03307837
- Testing
- CA-008
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Concentric Analgesics
Allergic Bronchopulmonary Aspergillosis
Phase 1 Three Part SAD, MAD & Cross-Over Study of ZP-059 in Healthy and Asthmatic Subjects
The primary safety objectives were: Part 1: To determine the safety and tolerability of single doses of ZP-059 in healthy subjects Part 2: To determine the safety and tolerability of multiple doses of ZP-059 in subjects with mild…
- Trial name
- NCT04229303
- Testing
- Voriconazole inhaled, oral voriconazole
- Where
- United Kingdom
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Zambon SpA
Anxiety Disorder Social, Anxiety
A Study of the Efficacy of Botox in the Treatment of Social Anxiety Disorder
The goal of this study is to see whether Botox is an effective treatment for social anxiety disorder (SAD). Participants will complete two short surveys on depression and anxiety symptoms, receive a one-time injection of Botox…
- Trial name
- NCT03078270
- Testing
- botulinum toxin A
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Daniel Lieberman